{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:06:14Z","timestamp":1790910374925,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,1,12]],"date-time":"2017-01-12T00:00:00Z","timestamp":1484179200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00432-016-2321-2","type":"journal-article","created":{"date-parts":[[2017,1,12]],"date-time":"2017-01-12T13:17:31Z","timestamp":1484227051000},"page":"843-850","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib"],"prefix":"10.1007","volume":"143","author":[{"given":"Markus","family":"Pfirrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dobromira","family":"Evtimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Saussele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena S.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Gugliotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Hasford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,12]]},"reference":[{"issue":"6","key":"2321_CR1","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim D-W, Larson RA, Lipton JH, Mahon F-X, Martinelli G, Mayer J, M\u00fcller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Sau\u00dfele S, Schiffer C, Silver R, Simonsson B, Steegmann J-L, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884. doi: 10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"issue":"9460","key":"2321_CR2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(05)17945-8","volume":"365","author":"M Bocchia","year":"2005","unstructured":"Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A, Amabile M, Forconi F, Gozzetti A, Raspadori D, Amadori S, Lauria F (2005) Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365(9460):657\u2013662. doi: 10.1016\/S0140-6736(05)17945-8","journal-title":"Lancet"},{"issue":"23","key":"2321_CR3","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.V126.23.597.597","volume":"126","author":"M Bonifacio","year":"2015","unstructured":"Bonifacio M, Scaffidi L, Binotto G, De Marchi F, Maino E, Calistri E, Bonalumi A, Frison L, Marin L, Medeot M, De Matteis G, Fanin R, Semenzato G, Ambrosetti A, Tiribelli M (2015) Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with standard dose imatinib: a study from the \u201cGruppo Triveneto LMC\u201d. Blood 126(23):597 (abstract)","journal-title":"Blood"},{"issue":"11","key":"2321_CR4","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.1158\/0008-5472.CAN-07-0302","volume":"67","author":"KM Brauer","year":"2007","unstructured":"Brauer KM, Werth D, von Schwarzenberg K, Bringmann A, Kanz L, Grunebach F, Brossart P (2007) BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res 67(11):5489\u20135497. doi: 10.1158\/0008-5472.CAN-07-0302","journal-title":"Cancer Res"},{"issue":"21","key":"2321_CR5","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1182\/blood.V120.21.1680.1680","volume":"120","author":"F Castagnetti","year":"2012","unstructured":"Castagnetti F, Gugliotta G, Palandri F, Breccia M, Stagno F, Levato L, Fava C, Luciano L, Intermesoli T, Cedrone M, Carella AM, Cavazzini F, Turri D, Avanzini P, Pierri I, Lunghi M, Venturi C, Soverini S, Testoni N, Alimena G, Saglio G, Martinelli G, Pane F, Baccarani M, Rosti G (2012) The BCR-ABL1 transcript type does not influence the response and the outcome of chronic myeloid leukemia patients treated frontline with nilotinib. Blood 120(21):1680 (abstract)","journal-title":"Blood"},{"key":"2321_CR6","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/sim.1070","volume":"21","author":"JB Choudhury","year":"2002","unstructured":"Choudhury JB (2002) Non-Parametric confidence interval estimation for competing risks analysis: application to contraceptive data. Stat Med 21:1129\u20131144","journal-title":"Stat Med"},{"issue":"446","key":"2321_CR7","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94(446):496\u2013509","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"2321_CR8","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ (1988) A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16(3):1141\u20131154","journal-title":"Ann Stat"},{"issue":"9","key":"2321_CR9","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3324\/haematol.2013.096537","volume":"99","author":"B Hanfstein","year":"2014","unstructured":"Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, Fabarius A, Proetel U, Schnittger S, Haferlach C, Krause SW, Schubert J, Einsele H, Hanel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Muller MC, Sakk, the German CMLSG (2014) Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica 99(9):1441\u20131447. doi: 10.3324\/haematol.2013.096537","journal-title":"Haematologica"},{"issue":"4","key":"2321_CR10","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1046\/j.1365-2141.1998.01098.x","volume":"103","author":"C Haskovec","year":"1998","unstructured":"Haskovec C, Ponzetto C, Polak J, Maritano D, Zemanova Z, Serra A, Michalova K, Klamova H, Cermak J, Saglio G (1998) P230 BCR\/ABL protein may be associated with an acute leukaemia phenotype. Br J Haematol 103(4):1104\u20131108","journal-title":"Br J Haematol"},{"issue":"6","key":"2321_CR11","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/blood.V88.6.2236.bloodjournal8862236","volume":"88","author":"A Hochhaus","year":"1996","unstructured":"Hochhaus A, Reiter A, Skladny H, Melo JV, Sick C, Berger U, Guo JQ, Arlinghaus RB, Hehlmann R, Goldman JM, Cross NC (1996) A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood 88(6):2236\u20132240","journal-title":"Blood"},{"key":"2321_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.246","author":"VS Hoffmann","year":"2016","unstructured":"Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF, Turkina A, Zackova D, Ossenkoppele G, Zaritskey A, Hoglund M, Simonsson B, Indrak K, Sninska Z, Sacha T, Clark R, Bogdanovic A, Hellmann A, Griskevicius L, Schubert-Fritschle G, Sertic D, Guilhot J, Lejniece S, Zupan I, Burgstaller S, Koskenvesa P, Everaus H, Costeas P, Lindoerfer D, Rosti G, Saussele S, Hochhaus A, Hehlmann R (2016) Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia. doi: 10.1038\/leu.2016.246","journal-title":"Leukemia"},{"issue":"10","key":"2321_CR13","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","volume":"127","author":"P Jain","year":"2016","unstructured":"Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O\u2019Brien S, Cortes J (2016) Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood 127(10):1269\u20131275. doi: 10.1182\/blood-2015-10-674242","journal-title":"Blood"},{"key":"2321_CR14","volume-title":"The statistical analysis of failure time data","author":"JD Kalbfleisch","year":"1980","unstructured":"Kalbfleisch JD, Prentice RL (1980) The statistical analysis of failure time data. Wiley, New York"},{"issue":"10","key":"2321_CR15","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3324\/haematol.2009.009134","volume":"94","author":"CM Lucas","year":"2009","unstructured":"Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, Wang L, Clark RE (2009) Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica 94(10):1362\u20131367. doi: 10.3324\/haematol.2009.009134","journal-title":"Haematologica"},{"issue":"7","key":"2321_CR16","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","volume":"88","author":"JV Melo","year":"1996","unstructured":"Melo JV (1996) The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88(7):2375\u20132384","journal-title":"Blood"},{"issue":"1","key":"2321_CR17","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/bjh.13184","volume":"169","author":"M Molica","year":"2015","unstructured":"Molica M, Zacheo I, Diverio D, Alimena G, Breccia M (2015) Long-term outcome of chronic myeloid leukaemia patients with p210 and p190 co-expression at baseline. Br J Haematol 169(1):148\u2013150. doi: 10.1111\/bjh.13184","journal-title":"Br J Haematol"},{"issue":"Suppl 2","key":"2321_CR18","doi-asserted-by":"publisher","first-page":"S209","DOI":"10.1007\/s00277-015-2316-0","volume":"94","author":"M Pfirrmann","year":"2015","unstructured":"Pfirrmann M, Lauseker M, Hoffmann VS, Hasford J (2015) Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death. Ann Hematol 94(Suppl 2):S209\u2013S218. doi: 10.1007\/s00277-015-2316-0","journal-title":"Ann Hematol"},{"issue":"1","key":"2321_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","volume":"30","author":"M Pfirrmann","year":"2016","unstructured":"Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, Hoffmann VS, Castagnetti F, Hasford J, Hehlmann R, Simonsson B (2016) Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 30(1):48\u201356. doi: 10.1038\/leu.2015.261","journal-title":"Leukemia"},{"issue":"3","key":"2321_CR20","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1046\/j.1365-2141.1999.01736.x","volume":"107","author":"F Ravandi","year":"1999","unstructured":"Ravandi F, Cortes J, Albitar M, Arlinghaus R, Qiang Guo J, Talpaz M, Kantarjian HM (1999) Chronic myelogenous leukaemia with p185(BCR\/ABL) expression: characteristics and clinical significance. Br J Haematol 107(3):581\u2013586","journal-title":"Br J Haematol"},{"issue":"10","key":"2321_CR21","first-page":"1648","volume":"9","author":"The Italian Cooperative Study Group on Chronic Myeloid Leukemia","year":"1995","unstructured":"The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1995) Chronic myeloid leukemia, BCR\/ABL transcript, response to interferon, and survival. Leukemia 9(10):1648\u20131652","journal-title":"Leukemia"},{"key":"2321_CR22","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling survival data: extending the cox model","author":"TM Therneau","year":"2000","unstructured":"Therneau TM, Grambsch PM (2000) Modeling survival data: extending the cox model. Springer, New York"},{"issue":"12","key":"2321_CR23","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1182\/blood.V87.12.5213.bloodjournal87125213","volume":"87","author":"F Rhee van","year":"1996","unstructured":"van Rhee F, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC (1996) p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood 87(12):5213\u20135217","journal-title":"Blood"},{"issue":"11","key":"2321_CR24","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1182\/blood-2009-02-204693","volume":"114","author":"D Verma","year":"2009","unstructured":"Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, Rios MB, Cortes J (2009) Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood 114(11):2232\u20132235. doi: 10.1182\/blood-2009-02-204693","journal-title":"Blood"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-016-2321-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-016-2321-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-016-2321-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T22:53:05Z","timestamp":1601333585000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-016-2321-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,12]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["2321"],"URL":"https:\/\/doi.org\/10.1007\/s00432-016-2321-2","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,12]]}}}